News

Acticor Biotech, Primer Capital's portfolio project, announces its projected IPO on the Euronext Growth market in Paris

On April 26-30, 2021, Anton Lavrentiev, CEO of Primer Capital took part in the Big Challenges Summit at Sirius as a speaker in the mini-symposium "Technology Entrepreneurship: The Path to the New Economy".

Anton Lavrentiev at the "Venture Capital Market 2020: Trends and Challenges" panel at the central event of the Russian venture capital industry in Kazan.

Primer Capital portfolio project, Atlas has become the first company in Russia to receive marketing authorization for its kit which can simultaneously detect 6 mutations in the BRAF, EGFR, KRAS, NRAS, KIT, PDGFRA genes in tumor samples.

The CEO of Primer Capital, Anton Lavrentiev, spoke at the Private Equity and M&A conference on February 11-12, 2021.

Botkin.AI, a platform for analyzing and processing CT scans using AI using raised RUB 160 million in a round of funding.

The fund won the Best Syndicated Deal nomination for its investment in Botkin.AI project

Primer Capital's portofolio project, a France-based clinical stage biotechnology company today announced the completion of its Dose Escalation Phase of Glenzocimab Study.

US-based Athira Pharma, a project financed by Primer Capital, is planning to go public.

The GemoPharm company was announced the winner of the scientific track within the acceleration program by AstraZeneca Skolkovo StartUp Challenge 2020.